Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Adaptive Dose-escalation Trial of PG-102 in MASLD/MASH with Increased Intestinal Permeability
KCT0012302Phase 2Not yet recruiting
- Sponsor
- PROGEN
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of PG-102 in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by PROGEN. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
PG-102
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on KCT0012302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012302.